Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 119
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00415779 | ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer | ||
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma | ||
| NCT07290894 | Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01 | ||
| NCT03503786 | Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer | ||
| NCT04091204 | Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study | ||
| NCT02408536 | Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer | ||
| NCT06905145 | Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis | ||
| NCT00657878 | Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval | ||
| NCT06886282 | Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney Disease | ||
| NCT04854213 | PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) | ||
| NCT01481545 | Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer | ||
| NCT06884878 | Multi-omic Approach to Cancer Diagnosis: the Italian Network of Excellence for Advanced Diagnosis (INNOVA) | ||
| NCT03891485 | Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy | ||
| NCT04071704 | Assessing Health-related Quality of Life in Sarcoma Patients | ||
| NCT00403429 | MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer | ||
| NCT01656551 | MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer | ||
| NCT04310176 | Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer | ||
| NCT04123925 | Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study | ||
| NCT05733806 | Study on Gynecological Rare Cancers | ||
| NCT00526396 | STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing Study | ||
| NCT04129255 | Octreotide LAR in the Induction of Immunologic Response in NENs Patients | ||
| NCT00331097 | ELDA: Elderly Breast Cancer - Docetaxel in Adjuvant Treatment | ||
| NCT04317092 | Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) | ||
| NCT02364791 | A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures | ||
| NCT01801904 | A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer | ||
| NCT01802749 | Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer | ||
| NCT07027046 | Application of da Vinci SP for Endometrial Cancer Surgical Staging | ||
| NCT05818865 | "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+. | ||
| NCT04893356 | Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT) | ||
| NCT06032975 | PRO for Fighting FT in Ovarian Cancer | ||
| NCT04397601 | Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal Cancer | ||
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | ||
| NCT00996983 | Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With Cancer | ||
| NCT02069067 | Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated | ||
| NCT02784171 | Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma | ||
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | ||
| NCT07577206 | Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia. | ||
| NCT05818020 | Multidisciplinary Integrated Platform for a Technological Innvovative Approach to Oncotherapies | ||
| NCT05817227 | Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer. | ||
| NCT06866093 | The Study is Observational and Retrospective: Lifestyle, BMI and Activity Physical. | ||
| NCT00431704 | VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer | ||
| NCT01061619 | Pathway to Diagnosis of Ovarian Cancer | ||
| NCT01651026 | Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer | ||
| NCT00401427 | HERVIN: Trastuzumab and Vinorelbine in Metastatic Breast Cancer | ||
| NCT07459920 | Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden | ||
| NCT05233982 | MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal Cancer | ||
| NCT06236464 | Identification of the Pathogenetic Mechanisms Underlying Squamous Cell Carcinomas | ||
| NCT00540800 | BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer | ||
| NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 | ||
| NCT04425239 | Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer |
